Burman W - Search Results

1

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. Weiner M, et al. Among authors: burman w. Antimicrob Agents Chemother. 2010 Oct;54(10):4192-200. doi: 10.1128/AAC.00353-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660695 Free PMC article. Clinical Trial.

2

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T; Tuberculosis Trials Consortium. Weiner M, et al. Among authors: burman w. Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7. doi: 10.1164/rccm.200208-951OC. Epub 2003 Jan 16. Am J Respir Crit Care Med. 2003. PMID: 12531776 Clinical Trial.

3

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.

Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Weiner M, et al. Among authors: burman w. Antimicrob Agents Chemother. 2007 Aug;51(8):2861-6. doi: 10.1128/AAC.01621-06. Epub 2007 May 21. Antimicrob Agents Chemother. 2007. PMID: 17517835 Free PMC article. Clinical Trial.

4

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.

Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S; Tuberculosis Trials Consortium. Weiner M, et al. Am J Respir Crit Care Med. 2004 Jun 1;169(11):1191-7. doi: 10.1164/rccm.200311-1612OC. Epub 2004 Feb 12. Am J Respir Crit Care Med. 2004. PMID: 14962821 Clinical Trial.

5

Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.

Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA; Tuberculosis Trials Consortium. Benator DA, et al. Pharmacotherapy. 2007 Jun;27(6):793-800. doi: 10.1592/phco.27.6.793. Pharmacotherapy. 2007. PMID: 17542762 Clinical Trial.

6

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium. Weiner M, et al. Among authors: burman w. Clin Infect Dis. 2005 May 15;40(10):1481-91. doi: 10.1086/429321. Epub 2005 Apr 14. Clin Infect Dis. 2005. PMID: 15844071 Clinical Trial.

7

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.

Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z; Tuberculosis Trials Consortium. Weiner M, et al. Among authors: burman w. Clin Infect Dis. 2005 Nov 1;41(9):1343-9. doi: 10.1086/496980. Epub 2005 Sep 29. Clin Infect Dis. 2005. PMID: 16206114

8

Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW. Weiner M, et al. Among authors: burman w. J Clin Microbiol. 2010 Dec;48(12):4370-6. doi: 10.1128/JCM.00757-10. Epub 2010 Oct 6. J Clin Microbiol. 2010. PMID: 20926712 Free PMC article.

9

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.

Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Savic RM, et al. Among authors: burman w. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10. Antimicrob Agents Chemother. 2014. PMID: 24614383 Free PMC article. Clinical Trial.

10

Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Weiner M, et al. J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. doi: 10.1093/jpids/pit077. Epub 2014 Jan 16. J Pediatric Infect Dis Soc. 2014. PMID: 26625366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters